Replacing the Animal Component in SerumEvaluating Raw Materials for Inclusion in Optimized Hybridoma Media

With the scarcity of CGMP facilities spurring a production crisis, manufacturers need to optimize their processes and formulations for individual hybridoma cell lines and production systems.

External Link - article-5079.pdf

Articles in this issue

almost 25 years ago

Article

A Novel Mathematical Method for Quantitative Expression of Deviation from Zero-Order Drug Release

almost 25 years ago

Article

Six Sigma Can Give Contractors a Quality Advantage

almost 25 years ago

Article

Industry Changes OTC Labels as Deadline Approaches

almost 25 years ago

Article

A Report of the PQRI Workshop on Blend Uniformity

almost 25 years ago

Article

Are You Ready for Global Manufacturing?

almost 25 years ago

Article

Pharmaceutical Coverage and Costs

almost 25 years ago

Article

Outsourcing Outlook

almost 25 years ago

Article

The Future State of Computer Validation, Part II: Increasing the Efficiency of Computer Validation Practices

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Replacing the Animal Component in SerumEvaluating Raw Materials for Inclusion in Optimized Hybridoma Media

Articles in this issue

Trending on Pharmaceutical Technology

Zumilokibart: Inside AbbVie's $10.9B Pipeline Bet

Why the First Generic Single-Dose Flu Antiviral Approval Matters

Germany Pharma Tariff Threat: What Manufacturers Need to Know

PharmTech Weekly Roundup—June 19, 2026

Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next